ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Catalent acquires drug services firm Juniper

by Michael McCoy
July 6, 2018 | APPEARED IN VOLUME 96, ISSUE 28

 

The drug delivery and development services firm Catalent has agreed to acquire Juniper Pharmaceuticals for $133 million. Juniper’s pharma services division offers drug industry customers solid-state and preclinical formulation screening as well as bioavailability enhancement technologies. Catalent says Juniper’s Nottingham, England, facility will be a European complement to its drug development centers in Somerset, N.J. and San Diego.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment